Patents by Inventor John Bridgeman

John Bridgeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11945876
    Abstract: Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: April 2, 2024
    Assignees: Instil Bio (UK) Limited, Instil Bio, Inc.
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou
  • Publication number: 20240058447
    Abstract: Provided herein are methods employing various fusion constructs in T cell therapy. The fusion constructs allow for one to reduce, to the point of full removal if desired, the use of IL-2 that would otherwise accompany an in vivo T cell therapy.
    Type: Application
    Filed: May 24, 2023
    Publication date: February 22, 2024
    Inventors: Owen R. Moon, Rubén Alvarez-Rodríguez, John Bridgeman
  • Publication number: 20230390552
    Abstract: Guidewires and methods for transmitting electrical stimuli to a heart and for guiding and supporting the delivery of elongate treatment devices within the heart are disclosed. A guidewire can comprise an elongate body, including first and second elongate conductors, and at least first and second electrodes. A distal end portion of the elongate body can include a preformed bias shape, such as a pigtail-shaped region, on which the first and second electrodes can be located. The preformed bias shape can optionally be non-coplanar relative to an intermediate portion of the elongate body. The first and second elongate conductors can be formed of a single structure or two or more electrically connected structures. The conductors can extend from proximal end portions to distal end portions that electrically connect to the first and second electrodes.
    Type: Application
    Filed: August 10, 2023
    Publication date: December 7, 2023
    Applicants: Teleflex Life Sciences Limited, Cardiac Interventions and Aviation LLC
    Inventors: David Daniels, Chad Kugler, John Bridgeman, Derek Stratton, Dean Peterson, Joshua Brenizer
  • Publication number: 20230331808
    Abstract: The present invention relates to a chimeric molecule useful in adoptive cell therapy (ACT), and cells comprising the same. The chimeric molecule can act as a modulator of cellular activity enhancing responses when an endogenous T-cell receptor (TCR) is engaged with its cognate antigen. The present invention also provides proteins, nucleic acids encoding the chimeric molecule and therapeutic uses thereof.
    Type: Application
    Filed: May 12, 2023
    Publication date: October 19, 2023
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Sujita Sukumaran, Xingliang Zhou, Eric Gschweng
  • Publication number: 20230277670
    Abstract: The present invention relates to a chimeric molecule useful in adoptive cell therapy (ACT), and cells comprising the same. The chimeric molecule can act as a modulator of cellular activity enhancing responses when an endogenous T-cell receptor (TCR) is engaged with its cognate antigen. The present invention also provides proteins, nucleic acids encoding the chimeric molecule and therapeutic uses thereof.
    Type: Application
    Filed: July 16, 2021
    Publication date: September 7, 2023
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez
  • Publication number: 20230227576
    Abstract: The present invention relates to a chimeric costimulatory antigen receptor (CoStAR) useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. The CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. The present invention also provides CoStAR proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof.
    Type: Application
    Filed: January 19, 2023
    Publication date: July 20, 2023
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou, Michael Gavin King
  • Patent number: 11697677
    Abstract: The present invention relates to a chimeric molecule useful in adoptive cell therapy (ACT), and cells comprising the same. The chimeric molecule can act as a modulator of cellular activity enhancing responses when an endogenous T-cell receptor (TCR) is engaged with its cognate antigen. The present invention also provides proteins, nucleic acids encoding the chimeric molecule and therapeutic uses thereof.
    Type: Grant
    Filed: August 25, 2022
    Date of Patent: July 11, 2023
    Assignee: INSTIL BIO (UK) LIMITED
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Sujita Sukumaran, Xingliang Zhou, Eric Gschweng
  • Publication number: 20230059511
    Abstract: The present invention relates to a chimeric molecule useful in adoptive cell therapy (ACT), and cells comprising the same. The chimeric molecule can act as a modulator of cellular activity enhancing responses when an endogenous T-cell receptor (TCR) is engaged with its cognate antigen. The present invention also provides proteins, nucleic acids encoding the chimeric molecule and therapeutic uses thereof.
    Type: Application
    Filed: August 25, 2022
    Publication date: February 23, 2023
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez
  • Publication number: 20230055694
    Abstract: Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.
    Type: Application
    Filed: September 28, 2022
    Publication date: February 23, 2023
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou
  • Publication number: 20230028504
    Abstract: This patent document discloses perfusion catheters and related methods for treating blood vessel lesions and abnormalities. A perfusion catheter can include an inflatable balloon, an elongate shaft operably attached to the balloon, and an optional containment structure surrounding at least a portion of the balloon. The balloon can be inflated until its outer surface contacts a wall of a blood vessel. When inflated, the balloon's inner surface defines a passage for blood to flow. The balloon can be configured to release one or more substances formulated to treat a tissue at or near the wall of a blood vessel. In an example, the balloon can include a bioactive layer, which comprises the one or more substances, overlaying an optional base layer. In an example, the balloon can include multiple filars, at least one of which is configured to elute the one or more substances through a perforation or hole in the filar.
    Type: Application
    Filed: September 30, 2022
    Publication date: January 26, 2023
    Applicant: Teleflex Life Sciences Limited
    Inventors: John Bridgeman, Peter Jacobs, Dean Peterson, Joshua Brenizer, Loic Van Horne
  • Publication number: 20230002470
    Abstract: The present invention relates to a chimeric costimulatory antigen receptor (CoStAR) useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. The CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. The present invention also provides CoStAR proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof.
    Type: Application
    Filed: August 30, 2022
    Publication date: January 5, 2023
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa
  • Publication number: 20230002504
    Abstract: Some embodiments provided herein are chimeric costimulatory antigen receptor (CoStAR), useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. In some embodiments, the CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. In some embodiments, CoStAR and/or fusion proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof are also provided.
    Type: Application
    Filed: June 15, 2022
    Publication date: January 5, 2023
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa, Milena Kalaitsidou
  • Patent number: 11511086
    Abstract: This patent document discloses perfusion catheters and related methods for treating blood vessel lesions and abnormalities. A perfusion catheter can include an inflatable balloon, an elongate shaft operably attached to the balloon, and an optional containment structure surrounding at least a portion of the balloon. The balloon can be inflated until its outer surface contacts a wall of a blood vessel. When inflated, the balloon's inner surface defines a passage for blood to flow. The balloon can be configured to release one or more substances formulated to treat a tissue at or near the wall of a blood vessel. In an example, the balloon can include a bioactive layer, which comprises the one or more substances, overlaying an optional base layer. In an example, the balloon can include multiple filars, at least one of which is configured to elute the one or more substances through a perforation or hole in the filar.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: November 29, 2022
    Assignee: Teleflex Life Sciences Limited
    Inventors: John Bridgeman, Peter Jacobs, Dean Peterson, Joshua Brenizer, Loic Van Horne
  • Publication number: 20220348631
    Abstract: The present invention relates to a chimeric costimulatory antigen receptor (CoStAR) useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. The CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. The present invention also provides CoStAR proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof.
    Type: Application
    Filed: June 17, 2022
    Publication date: November 3, 2022
    Inventors: John Bridgeman, Robert Hawkins, Ruben Rodriguez, Gray Kueberuwa
  • Publication number: 20220339432
    Abstract: Guidewires and methods for transmitting electrical stimuli to a heart and for guiding and supporting the delivery of elongate treatment devices within the heart are disclosed. A guidewire can comprise an elongate body, including first and second elongate conductors, and at least first and second electrodes. A distal end portion of the elongate body can include a preformed bias shape, such as a pigtail-shaped region, on which the first and second electrodes can be located. The preformed bias shape can optionally be non-coplanar relative to an intermediate portion of the elongate body. The first and second elongate conductors can be formed of a single structure or two or more electrically connected structures. The conductors can extend from proximal end portions to distal end portions that electrically connect to the first and second electrodes.
    Type: Application
    Filed: July 12, 2022
    Publication date: October 27, 2022
    Applicants: Teleflex Life Sciences Limited, Cardiac Interventions and Aviation LLC
    Inventors: David Daniels, Chad Kugler, John Bridgeman, Derek Stratton, Dean Peterson, Joshua Brenizer
  • Patent number: 11420046
    Abstract: Guidewires and methods for transmitting electrical stimuli to a heart and for guiding and supporting the delivery of elongate treatment devices within the heart are disclosed. A guidewire can comprise an elongate body, including first and second elongate conductors, and at least first and second electrodes. A distal end portion of the elongate body can include a preformed bias shape, such as a pigtail-shaped region, on which the first and second electrodes can be located. The preformed bias shape can optionally be non-coplanar relative to an intermediate portion of the elongate body. The first and second elongate conductors can be formed of a single structure or two or more electrically connected structures. The conductors can extend from proximal end portions to distal end portions that electrically connect to the first and second electrodes.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: August 23, 2022
    Assignees: Cardiac Interventions and Aviation LLC, Teleflex Life Sciences Limited
    Inventors: David Daniels, Chad Kugler, John Bridgeman, Derek Stratton, Dean Peterson, Joshua Brenizer
  • Publication number: 20220160760
    Abstract: The present invention relates to a cell comprising a chimeric costimulatory antigen receptor (CoStAR) useful in adoptive cell therapy (ACT). The CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. The present invention also provides CoStAR proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof.
    Type: Application
    Filed: June 29, 2021
    Publication date: May 26, 2022
    Inventors: John Bridgeman, Robert Hawkins
  • Patent number: 11160952
    Abstract: Catheters and methods for supporting a guidewire or delivering a radiopaque, diagnostic or therapeutic agent through a vessel stenosis or other tortuous anatomy are disclosed. A catheter can comprise an elongate shaft body and a tip member disposed at a distal end of the shaft body. The shaft body can extend from a proximal end to the distal end and can define an inner lumen. The shaft body can include a liner, a braid member surrounding the liner, a multi-layer coil surrounding the braid member, and a polymer cover surrounding the multi-layer coil. An outer surface portion of the polymer cover can include one or more helical threads, which can be enveloped in an outer wrapper. The tip member can be made from a metal or a polymer. Polymer tip members can include a hard or semi-hard distal tip.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: November 2, 2021
    Assignee: Teleflex Life Sciences Limited
    Inventors: John Bridgeman, Daniel Jindra, Peter Bo
  • Publication number: 20210212721
    Abstract: In an example, a scoring device is configured for retention of a catheter shaft. The scoring device incudes a proximal portion and a distal portion. A retention sleeve extends between the proximal and distal portions. The retention sleeve has a catheter socket configured to selectively receive and mechanically engage the catheter shaft. The scoring device includes a scoring tool coupled with the retention sleeve, for instance proximate to the distal portion. The scoring tool includes a balloon socket configured to selectively receive a balloon of the catheter shaft. The scoring tool includes one or more scoring elements extending around the balloon socket, the one or more scoring elements configured to provide localized scoring to vasculature.
    Type: Application
    Filed: December 20, 2020
    Publication date: July 15, 2021
    Inventors: Derek Stratton, John Bridgeman
  • Publication number: 20210015517
    Abstract: Catheters and methods for supporting a guidewire or delivering a radiopaque, diagnostic or therapeutic agent through a vessel stenosis or other tortuous anatomy are disclosed. A catheter can comprise an elongate shaft body and a tip member disposed at a distal end of the shaft body. The shaft body can extend from a proximal end to the distal end and can define an inner lumen. The shaft body can include a liner, a braid member surrounding the liner, a multi-layer coil surrounding the braid member, and a polymer cover surrounding the multi-layer coil. The multi-layer coil can include first and second coil layers wound in opposing directions. An outer surface portion of the polymer cover can include one or more helical threads. The tip member can be made from a metal or a polymer and can also include one or more helical threads around its outer surface.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 21, 2021
    Applicant: Teleflex Life Sciences Limited
    Inventors: Howard C. Root, John Bridgeman, Steve Michael, Gregg S. Sutton, Karl V. Ganske